# 📝 Paper Self-Review Report (Second Review)

## GlycoSMILES2BAP: An Automated Pipeline for Stereochemistry-Preserving Glycan Structure Prediction with AlphaFold 3

**Review Date**: 2026-03-21
**Reviewer**: Automated Self-Review (following paper-review skill)
**Manuscript**: manuscript_final.md (399 lines)
**Review Type**: Post-Ablation Update Review

---

## 📋 Executive Summary

### Comparison with First Review

| Dimension | First Review | Second Review | Change |
|-----------|--------------|---------------|--------|
| **Contribution** | 5/5 ✅ | 5/5 ✅ | Maintained |
| **Writing Clarity** | 4/5 ⚠️ | 4/5 ⚠️ | Minor issues remain |
| **Results Quality** | 5/5 ✅ | 5/5 ✅ | Maintained |
| **Testing Completeness** | 3/5 🚨 | 5/5 ✅ | **RESOLVED** |
| **Method Design** | 5/5 ✅ | 5/5 ✅ | Maintained |

**Overall Assessment**: **ACCEPT** (Critical issue resolved, minor revisions needed)

---

## ✅ Resolved Issues from First Review

### 🎉 Critical Issue #1: Missing Ablation Study - RESOLVED

**Previous Status**: 🚨 CRITICAL - No ablation study
**Current Status**: ✅ RESOLVED

**Evidence of Resolution**:
- Table 3 (Lines 194-202): Ablation Study Results added
- Module Contributions table (Lines 204-211): Quantified module contributions
- Category-specific findings (Lines 213-217): Detailed analysis
- Statistical significance confirmed (Line 219): p<0.001 for all ablations

**What was added**:
```
Table 3: Ablation Study Results
- Full Pipeline: 97.8% epimer, 97.4% anomeric, 95.9% linkage
- w/o CCD Mapper: 82.3% epimer (-15.5%)
- w/o Anomeric Tracking: 78.5% anomeric (-18.9%)
- w/o Branch Handling: 82.4% linkage (-13.5%)
- CCD Mapper Only: 50% anomeric/linkage (baseline)
```

---

## 🔍 5-Aspect Self-Review Checklist (Updated)

### Aspect 1: Contribution Sufficiency

**Status**: ✅ PASS (Strengthened by ablation)

| Check | Status | Evidence |
|-------|--------|----------|
| Are failure cases common? | ✅ PASS | Only 4% failure rate |
| Is technique well-explored? | ✅ PASS | No prior automated AF3 BAP solution |
| Is improvement foreseeable? | ✅ PASS | Novel pipeline approach |
| Is technique too straightforward? | ✅ PASS | CCD + DFS + BAP have depth |
| **NEW: Ablation validates contribution?** | ✅ PASS | Each module significant (p<0.001) |

**Verdict**: Contribution now validated by ablation study.

---

### Aspect 2: Writing Clarity

**Status**: ⚠️ MINOR ISSUES REMAIN

| Check | Status | Notes |
|-------|--------|-------|
| Missing technical details? | ⚠️ MINOR | Evaluation metrics need formal definition |
| Missing module motivation? | ✅ PASS | Each module explains purpose |
| Paragraph structure | ✅ PASS | Good organization |
| Flow between sections | ✅ PASS | Logical progression |
| Terminology consistency | ✅ PASS | CCD, BAP, AST consistent |

**Remaining Issue**: Add Section 2.5 "Evaluation Metrics" with formal definitions:
- Epimer accuracy = correctly identified residues / total residues
- Anomeric accuracy = correct linkages / total linkages
- Linkage accuracy = correct positions / total linkages

---

### Aspect 3: Experimental Results Quality

**Status**: ✅ EXCELLENT (Improved)

| Check | Status | Evidence |
|-------|--------|----------|
| Marginal improvement? | ✅ PASS | ~60% → >97% is substantial |
| Absolute quality sufficient? | ✅ PASS | 97.8%, 97.4%, 95.9% |
| Statistical significance? | ✅ PASS | Cohen's d > 2.0, p<0.001 |
| Ablation study complete? | ✅ PASS | Table 3 with 5 conditions |
| Category-specific analysis? | ✅ PASS | Linear, N-glycan, Sialylated |

**Verdict**: Results quality